Subtopic Deep Dive

Gut Microbiota in Functional Bowel Disorders
Research Guide

What is Gut Microbiota in Functional Bowel Disorders?

Gut Microbiota in Functional Bowel Disorders examines microbial dysbiosis in irritable bowel syndrome (IBS), functional constipation, and related disorders through metagenomic profiling and modulation interventions.

Researchers use 16S rRNA sequencing and shotgun metagenomics to identify altered Firmicutes/Bacteroidetes ratios in IBS patients (Stojanov et al., 2020). Studies link gut-brain axis disruptions to symptom severity via microbiota influences on enteric nervous system signaling (Cryan et al., 2019; Carabotti et al., 2015). Over 20 papers since 2015 correlate microbiota composition with Rome IV-defined gut-brain interaction disorders (Drossman and Hasler, 2016).

15
Curated Papers
3
Key Challenges

Why It Matters

Microbiota dysbiosis in functional bowel disorders drives symptom persistence, enabling probiotic interventions that restore Firmicutes/Bacteroidetes balance and reduce inflammation (Stojanov et al., 2020). Gut-brain axis research reveals microbiota modulation improves IBS outcomes via short-chain fatty acid signaling (Silva et al., 2020; Cryan et al., 2019). Global prevalence data highlight microbiota-targeted diagnostics for 10-20% worldwide affected by IBS and functional dyspepsia (Sperber et al., 2020). These advances support fecal microbiota transplants and prebiotics in clinical guidelines (Marchesi et al., 2015).

Key Research Challenges

Heterogeneity in Dysbiosis Profiles

IBS subtypes show variable Firmicutes/Bacteroidetes shifts, complicating universal biomarkers (Stojanov et al., 2020). Metagenomic studies reveal inconsistent taxa associations across populations (Sperber et al., 2020). Standardization of stool sampling and sequencing depth remains unresolved (Marchesi et al., 2015).

Causality vs Correlation

Cross-sectional designs fail to distinguish microbiota changes causing symptoms from disease effects (Cryan et al., 2019). Longitudinal trials with probiotics show mixed causality evidence (Silva et al., 2020). Animal models suggest bidirectional gut-brain influences but lack human validation (Carabotti et al., 2015).

Modulation Intervention Efficacy

Probiotic strains yield variable symptom relief in IBS due to strain-specific colonization (Stojanov et al., 2020). Fecal transplants improve permeability but face safety concerns (Bischoff et al., 2014). Dose-response data for short-chain fatty acids in gut-brain signaling are preliminary (Silva et al., 2020).

Essential Papers

1.

The Microbiota-Gut-Brain Axis

John F. Cryan, Kenneth J. O’Riordan, Caitlin S.M. Cowan et al. · 2019 · Physiological Reviews · 4.3K citations

The importance of the gut-brain axis in maintaining homeostasis has long been appreciated. However, the past 15 yr have seen the emergence of the microbiota (the trillions of microorganisms within ...

2.

The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.

Marilia Carabotti, Annunziata Scirocco, M.A. Maselli et al. · 2015 · PubMed · 2.6K citations

The gut-brain axis (GBA) consists of bidirectional communication between the central and the enteric nervous system, linking emotional and cognitive centers of the brain with peripheral intestinal ...

3.

The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication

Ygor Parladore Silva, Andressa Bernardi, Rudimar Luiz Frozza · 2020 · Frontiers in Endocrinology · 2.6K citations

A substantial body of evidence supports that the gut microbiota plays a pivotal role in the regulation of metabolic, endocrine and immune functions. In recent years, there has been growing recognit...

4.

The gut microbiota and host health: a new clinical frontier

Julian R. Marchesi, David Adams, Francesca Fava et al. · 2015 · Gut · 2.2K citations

Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologie...

5.

Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study

Ami D. Sperber, Shrikant I. Bangdiwala, Douglas A. Drossman et al. · 2020 · Gastroenterology · 2.0K citations

6.

The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease

Spase Stojanov, Aleš Berlec, Borut Štrukelj · 2020 · Microorganisms · 1.8K citations

The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely ac...

7.

Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction

Douglas A. Drossman, William L. Hasler · 2016 · Gastroenterology · 1.7K citations

Reading Guide

Foundational Papers

Start with Cryan et al. (2019) for microbiota-gut-brain axis overview (4287 citations), then Carabotti et al. (2015) for enteric microbiota interactions (2585 citations), and Bischoff et al. (2014) for permeability links to dysbiosis (1630 citations).

Recent Advances

Study Sperber et al. (2020) for global FGID burden integrating microbiota data (1977 citations), Stojanov et al. (2020) for probiotic F/B modulation (1767 citations), and Silva et al. (2020) for short-chain fatty acids in gut-brain communication (2582 citations).

Core Methods

Core techniques include 16S rRNA/shotgun metagenomics for composition, metabolomics for short-chain fatty acids, and probiotic intervention trials assessing Rome IV symptoms (Marchesi et al., 2015; Stojanov et al., 2020).

How PapersFlow Helps You Research Gut Microbiota in Functional Bowel Disorders

Discover & Search

Research Agent uses searchPapers with query 'gut microbiota IBS dysbiosis Rome IV' to retrieve 50+ papers including Cryan et al. (2019, 4287 citations), then citationGraph maps connections to Drossman and Hasler (2016). findSimilarPapers on Sperber et al. (2020) uncovers global prevalence studies; exaSearch drills into Firmicutes/Bacteroidetes ratios from Stojanov et al. (2020).

Analyze & Verify

Analysis Agent applies readPaperContent to extract metagenomic methods from Marchesi et al. (2015), then runPythonAnalysis with pandas processes Firmicutes/Bacteroidetes ratios from Stojanov et al. (2020) abstracts for statistical significance (p<0.05 verification). verifyResponse via CoVe cross-checks dysbiosis claims against Cryan et al. (2019); GRADE grading scores probiotic evidence from Silva et al. (2020) as moderate quality.

Synthesize & Write

Synthesis Agent detects gaps in causality studies between Carabotti et al. (2015) and recent trials, flags contradictions in F/B ratio impacts (Stojanov et al., 2020). Writing Agent uses latexEditText for review drafts, latexSyncCitations integrates Sperber et al. (2020), and latexCompile generates polished manuscripts; exportMermaid visualizes gut-brain axis pathways from Cryan et al. (2019).

Use Cases

"Analyze Firmicutes/Bacteroidetes ratios in IBS metagenomics datasets from recent papers"

Research Agent → searchPapers('IBS Firmicutes Bacteroidetes') → Analysis Agent → runPythonAnalysis(pandas on extracted alpha-diversity stats from Stojanov et al., 2020) → matplotlib plots of ratio distributions with statistical tests.

"Draft LaTeX review on microbiota modulation in functional constipation"

Synthesis Agent → gap detection (probiotics in Rome IV disorders) → Writing Agent → latexEditText(structured sections), latexSyncCitations(Drossman and Hasler, 2016; Sperber et al., 2020) → latexCompile → PDF with gut-brain diagram.

"Find code for 16S rRNA analysis in gut microbiota IBS studies"

Research Agent → searchPapers('16S rRNA IBS microbiota') → Code Discovery (paperExtractUrls → paperFindGithubRepo on Marchesi et al., 2015 methods) → githubRepoInspect → QIIME2 pipelines for dysbiosis computation.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(250+ hits on 'gut microbiota functional bowel'), citationGraph clusters Cryan et al. (2019) hub, DeepScan 7-steps analyzes Sperber et al. (2020) prevalence with GRADE checkpoints. Theorizer generates hypotheses on short-chain fatty acid causality from Silva et al. (2020) + Carabotti et al. (2015), exporting Mermaid diagrams for modulation trials.

Frequently Asked Questions

What defines gut microbiota dysbiosis in functional bowel disorders?

Dysbiosis features elevated Firmicutes/Bacteroidetes ratios and reduced alpha-diversity in IBS per Rome IV criteria (Stojanov et al., 2020; Drossman and Hasler, 2016).

What methods profile microbiota in IBS?

16S rRNA sequencing and shotgun metagenomics quantify taxa abundances; short-chain fatty acid metabolomics links to gut-brain signaling (Marchesi et al., 2015; Silva et al., 2020).

What are key papers on this subtopic?

Cryan et al. (2019, 4287 citations) on microbiota-gut-brain axis; Sperber et al. (2020, 1977 citations) on global FGID prevalence; Stojanov et al. (2020) on F/B ratio modulation.

What open problems exist?

Establishing microbiota causality in symptoms requires longitudinal RCTs; strain-specific probiotic efficacy varies; personalized modulation strategies lack biomarkers (Cryan et al., 2019; Stojanov et al., 2020).

Research Gastrointestinal motility and disorders with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Gut Microbiota in Functional Bowel Disorders with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers